Medical technology developer PositiveID Corporation has claimed that its iglucose mobile health device had met all the requirements of telecom regulator FCC, clearing the last hurdle to sell the device in the United States.
FCC approval comes barely weeks after FDA gave its approval. The Florida-based company says its device avoids the need for diabetics to maintain heavy logbooks containing the readings of blood sugar in their bodies.
The iglucose device helps transmit the readings from glucometer to a diabetes management Web portal so that diabetics can share the information on glucose levels with family members, caregivers and clinicians.
iglucose eliminates the burden of keeping manual logbooks of glucose levels and empowers people to be more active with the management of their diabetes.
Data is transmitted via cellular networks. According to some reports, the company has wireless infrastructure agreements with AT&T in the United States and Rogers Communications in Canada.
Leading diabetes education organizations recommend that people with diabetes check their blood sugar, keep a logbook of their readings, and take them to their healthcare professional. This is a fundamental cornerstone of diabetes management.
Unfortunately, many people with diabetes do not keep logbooks. iglucose says it is now solving this problem by automating the process.
PositiveID is planning to launch the device in early next year.
“Successful passing of all FCC requirements so soon after FDA approval is a true testament to the level of excellence that PositiveID puts into all of their projects,” the company stated in a press release.
Narayan Bhat is a contributing editor for HealthTechZone. To read more of Narayan’s articles, please visit his columnist page.Edited by
Juliana Kenny
